Vaccine

Editorial Board/Aims and Scope
pp. CO2-CO2(1)

Meeting summary - Possibilities for active and passive vaccination against opportunistic infections
pp. 801-804(4)
Authors: Walker R.I.; Blanchard T.; Braun J.M.; Cebra J.J.; Cross A.S.; Fattom A.; Giannasca P.J.; Holder I.A.; Huebner J.; Matthews R.; Pier G.B.; Romani L.; von Specht B.U.; Trautmann M.

Interactions of commensal gut microbes with subsets of B- and T-cells in the murine host
pp. 805-811(7)
Authors: Jiang H.-Q.; Thurnheer M.C.; Zuercher A.W.; Boiko N.V.; Bos N.A.; Cebra J.J.

Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis
pp. 812-817(6)
Authors: Cross A.S.; Opal S.; Cook P.; Drabick J.; Bhattacharjee A.

O antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections
pp. 818-821(4)
Authors: Trautmann M.; Held T.K.; Cross A.S.

Enterococcal infections: host response, therapeutic, and prophylactic possibilities
pp. 822-830(9)
Authors: Koch S.; Hufnagel M.; Theilacker C.; Huebner J.

Pseudomonas immunotherapy: a historical overview
pp. 831-839(9)
Author: Holder I.A.

Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections
pp. 840-847(8)
Authors: Baumann U.; Mansouri E.; von Specht B.-U.

Active and passive immunization against Clostridium difficile diarrhea and colitis
pp. 848-856(9)
Authors: Giannasca P.J.; Warny M.

Dendritic cell-based vaccination against opportunistic fungi
pp. 857-864(8)
Authors: Bozza S.; Montagnoli C.; Gaziano R.; Rossi G.; Nkwanyuo G.; Bellocchio S.; Romani L.

Recombinant antibodies: a natural partner in combinatorial antifungal therapy
pp. 865-871(7)
Authors: Matthews R.C.; Burnie J.P.

Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide
pp. 872-879(8)
Authors: Maira-Litran T.; Kropec A.; Goldmann D.; Pier G.B.

Development of StaphVAX(TM), a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials
pp. 880-887(8)
Authors: Fattom A.I.; Horwith G.; Fuller S.; Propst M.; Naso R.

Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy
pp. 888-897(10)
Authors: Blanchard T.G.; Eisenberg J.C.; Matsumoto Y.

Neisseria meningitidis, Neisseria lactamica and Moraxella catarrhalis share cross-reactive carbohydrate antigens
pp. 898-908(11)
Authors: Braun J.M.; Beuth J.; Blackwell C.C.; Giersen S.; Higgins P.G.; Tzanakaki G.; Unverhau H.; Weir D.M.